- Home
- OTLK vs QNCX Comparison
OTLK vs QNCX Comparison
Compare OTLK & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- QNCX
- Stock Information
- Founded
- OTLK 2010
- QNCX 2012
- Country
- OTLK United States
- QNCX United States
- Employees
- OTLK N/A
- QNCX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OTLK Health Care
- QNCX Health Care
- Exchange
- OTLK Nasdaq
- QNCX Nasdaq
- Market Cap
- OTLK 48.3M
- QNCX 47.7M
- IPO Year
- OTLK 2016
- QNCX 2019
- Fundamental
- Price
- OTLK $1.57
- QNCX $1.53
- Analyst Decision
- OTLK Strong Buy
- QNCX Strong Buy
- Analyst Count
- OTLK 5
- QNCX 5
- Target Price
- OTLK $9.60
- QNCX $8.00
- AVG Volume (30 Days)
- OTLK 796.7K
- QNCX 336.8K
- Earning Date
- OTLK 08-13-2025
- QNCX 08-12-2025
- Dividend Yield
- OTLK N/A
- QNCX N/A
- EPS Growth
- OTLK N/A
- QNCX N/A
- EPS
- OTLK 0.83
- QNCX N/A
- Revenue
- OTLK N/A
- QNCX N/A
- Revenue This Year
- OTLK N/A
- QNCX N/A
- Revenue Next Year
- OTLK $379.84
- QNCX N/A
- P/E Ratio
- OTLK $1.91
- QNCX N/A
- Revenue Growth
- OTLK N/A
- QNCX N/A
- 52 Week Low
- OTLK $0.87
- QNCX $0.51
- 52 Week High
- OTLK $9.25
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- OTLK 40.37
- QNCX 66.23
- Support Level
- OTLK $1.65
- QNCX $1.43
- Resistance Level
- OTLK $2.04
- QNCX $1.68
- Average True Range (ATR)
- OTLK 0.12
- QNCX 0.13
- MACD
- OTLK -0.03
- QNCX 0.03
- Stochastic Oscillator
- OTLK 2.13
- QNCX 83.02
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.